國立高雄大學圖資館 |

登入

回首頁

Biomarkers for Huntington's diseaseimproving clinical outcomes /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Biomarkers for Huntington's diseaseedited by Elizabeth A. Thomas, Georgia M. Parkin.
其他題名:	improving clinical outcomes /
其他作者:	Thomas, Elizabeth A.
出版者:	Cham :Springer International Publishing :2023.
面頁冊數:	xvi, 475 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Huntington's diseaseDiagnosis.
電子資源:	https://doi.org/10.1007/978-3-031-32815-2
ISBN:	9783031328152$q(electronic bk.)

Biomarkers for Huntington's diseaseimproving clinical outcomes /
Biomarkers for Huntington's diseaseimproving clinical outcomes /[electronic resource] :edited by Elizabeth A. Thomas, Georgia M. Parkin. - Cham :Springer International Publishing :2023. - xvi, 475 p. :ill., digital ;24 cm. - Contemporary clinical neuroscience,2627-5341. - Contemporary clinical neuroscience..

Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

ISBN: 9783031328152$q(electronic bk.)

Standard No.: 10.1007/978-3-031-32815-2doiSubjects--Topical Terms:

962104
Huntington's disease
--Diagnosis.

LC Class. No.: RC394.H85 / B56 2023

Dewey Class. No.: 616.851075

Biomarkers for Huntington's diseaseimproving clinical outcomes /
LDR:02686nmm a2200325 a 4500 001 651754
003 DE-He213
005 20231012193305.0
006 m d
007 cr nn 008maaau
008 240327s2023 sz s 0 eng d
020 $a 9783031328152$q(electronic bk.)
020 $a 9783031328145$q(paper)
024 7 $a 10.1007/978-3-031-32815-2 $2 doi
035 $a 978-3-031-32815-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC394.H85 $b B56 2023
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 616.851075 $2 23
090 $a RC394.H85 $b B615 2023
245 0 0 $a Biomarkers for Huntington's disease $h [electronic resource] : $b improving clinical outcomes / $c edited by Elizabeth A. Thomas, Georgia M. Parkin.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xvi, 475 p. : $b ill., digital ; $c 24 cm.
490 1 $a Contemporary clinical neuroscience, $x 2627-5341
520 $a Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.
650 0 $a Huntington's disease $x Diagnosis. $3 962104
650 0 $a Biochemical markers. $3 195446
650 1 4 $a Neuroscience. $3 297547
650 2 4 $a Neurology. $3 211583
650 2 4 $a Neurophysiology. $3 194420
650 2 4 $a Neuropharmacology. $3 275141
700 1 $a Thomas, Elizabeth A. $3 962102
700 1 $a Parkin, Georgia M. $3 962103
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Contemporary clinical neuroscience. $3 712755
856 4 0 $u https://doi.org/10.1007/978-3-031-32815-2
950 $a Biomedical and Life Sciences (SpringerNature-11642)